Dyglomera and Semaglutide
Supplement–drug interaction evidence from the TruthStack database.
| Severity | MODERATE |
|---|---|
| Evidence Tier | Moderate |
| Interaction Type | PHARMACODYNAMIC RISK |
| Mechanism | PHARMACODYNAMIC, GASTROINTESTINAL |
| Last Reviewed | 2026-03-03 |
Source Verification
Attestation METHODOLOGY_ATTESTED
Corpus manifest 26b2d684...
Last reviewed 2026-03-03
Live attestation Query API — returns signed DAA ID per request
Data license CC BY 4.0
Summary
Dyglomera activates GLP-1 and DPP-4 pathways similar to semaglutide. Clinical trials showed fasting glucose reductions of 18.4% in metabolic syndrome patients. Combining with semaglutide may increase hypoglycemia risk and GI side effects. Monitor blood glucose and discuss with prescriber.
API Reference
GET https://api.truthstack.co/v1/check?c1=Dyglomera&c2=Semaglutide
Open, unauthenticated. Returns JSON. Developer documentation
Sources
Supporting: 26350732
Related Interactions
What this page is and is not. TruthStack is an informational reference database that describes published pharmacological findings. It does not provide medical advice, diagnosis, or treatment recommendations. The information on this page reflects flags in our database and should not replace consultation with a qualified healthcare provider. Always discuss supplement-drug combinations with your prescriber or pharmacist.